반복된 블레오마이신 주사로 유도한 피부경화증 쥐 모델에서 진피 두께 변화에 대한 연구

Abstract

Systemic sclerosis (SSc) is a chronic connective tissue disorder characterized by extensive fibrosis associated with increased deposition of extracellular matrix (ECM) proteins in the skin and various internal organs such as lung, heart, kidney, gastrointestinal tract and vascular injury. Scleroderma, sclerosis of the skin, is usually resistant to all kinds of treatments. The etiology and the initial events of SSc remain unclear. but, a number of cytokines are supposed to play a role in the induction fibrosis. Among them, transforming growth factor-β (TGF-β) is suggested to play a crucial role in tissue fibrosis. But, dermal fibrosis/sclerosis has not been fully elucidated. Bleomycin (BLM), originally isolated from the fungus Streptomyces verticillus, is a frequently used antitumor antibiotic effect against various kinds of cancers. It has side effects include pulmonary fibrosis. BLM induced lung fibrosis is a well-known animal model that mimics human pulmonary fibrosis histologically and biochemically. Upregulation of TGF-β expression in the lungs was reported in pulmonary fibrosis which increases in lung ECM production. Although animal models which exhibit all the aspects of scleroderma are not currently available, there are several animal models for research on the pathogenesis of SSc and on potential therapeutic agents. In particular a BLM induced scleroderma model involving daily subcutaneous injection of BLM into the back skin of susceptible strains of mice has been developed. In this study, we have attempted to establish a scleroderma animal model by subcutaneous injections of BLM. Our mouse model could provide an aid to analyse the etiology and therapeutic strategy of scleroderma and SSc.

Key Words : Bleomycin, Mouse model, Scleroderma, Systemic sclerosis